Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group
about
The impact of biological interventions for ulcerative colitis on health-related quality of lifeThe impact of biological interventions for ulcerative colitis on health-related quality of lifeThe impact of medical interventions for ulcerative colitis on health-related quality of lifeSpecialist nursing interventions for inflammatory bowel diseasePsychological interventions for treatment of inflammatory bowel diseaseSpecialist nursing interventions for inflammatory bowel diseasePsoriasis: epidemiology, clinical features, and quality of lifeAssessing health-related quality of life in patients with inflammatory bowel disease, in Crete, GreeceBenefit-risk assessment of golimumab in the treatment of refractory ulcerative colitisDiagnosis and management of functional symptoms in inflammatory bowel disease in remissionPharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsSCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobankingOptimising monitoring in the management of Crohn's disease: a physician's perspectiveEfficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled TrialsPreventive health measures in inflammatory bowel diseaseGolimumab for the treatment of ulcerative colitisHealth-related quality of life during natalizumab maintenance therapy for Crohn's diseaseBudesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trialsLow-dose naltrexone therapy improves active Crohn's diseaseLeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideMeasurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel diseaseCDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data.Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patientsPatient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease.Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of life.Opioid use is associated with decreased quality of life in patients with Crohn's disease.Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-control questionnaireFactors influencing health-related quality of life in chronic liver disease.Quality-of-life research on the Internet: feasibility and potential biases in patients with ulcerative colitis.Quality of life measurement in gastrointestinal and liver disorders.Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot studyMedical management of Crohn's disease.Randomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease.Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.Prevention of relapse of Crohn's disease.Association of symptoms with gastrointestinal microbiota in irritable bowel syndromeAssessing health status in inflammatory bowel disease using a novel single-item numeric rating scale.
P2860
Q24187078-6521ABB0-4246-49D9-ACB5-2559DFD5D63EQ24202509-300395CD-5B56-4D3E-9010-8E48F29A245EQ24235864-37534A58-8483-43BB-8447-36E3D625FC5DQ24240495-E9F6E07B-29CB-4FEB-B925-D6B2E05E3387Q24243610-21B5193A-65EC-4615-8774-195D65DA6BFBQ24244931-0D3A904D-D777-43D5-AC00-9DFF580103ACQ24675003-809883F5-A5E3-4134-AFC7-ED20F14497D8Q24802163-D8A17E8C-0A69-4D39-82A6-A08BDDC85A3AQ26764801-49C0DAAA-CB20-4478-8140-B2E75166716DQ26768264-499187DD-DCD5-4779-9B7D-DD4B2F3EF7FFQ26768280-556F8D98-5EF0-4C79-97F0-85953E21A668Q26853573-F2E489C8-A515-43E9-8E0B-9062D4263ADDQ27007083-B9AB058B-EFDC-40C3-9A10-B1B4D41C6E48Q28070298-E0703044-DF19-4120-A96C-98FF30D1903FQ28078112-D3A1EBB3-C85E-44ED-873F-CF3EDACBBD5BQ28236322-26580429-E366-4D49-89C2-4CB5641B6006Q28258882-0051BF26-9D22-48F5-BF15-3263A68F60B1Q28266279-D59C8B0A-34F9-4986-8B01-BFD161B436FFQ28283321-1175CE59-7B78-4D9D-AC7F-E75AB8361005Q28361611-6C758C9B-3AD9-4894-B1C3-EE8B32AD7AF0Q28361615-91FDF21E-8085-4ABE-A9C3-A83DE0C952BBQ30444398-BA7908DF-FAED-4F08-B723-495711927FB2Q30844786-D432970E-3D42-4233-A688-599FB6433CA3Q31140142-F3053D50-B36F-445C-93B6-6BDF1FB14C72Q33404394-16B02A92-7C88-473D-B5D2-D4E35A7E4B3FQ33536129-52EAC543-7145-4BA9-9F26-61AA1DC3A131Q33562464-7FDDFEE5-26A3-4199-B06B-DA63E072CEDDQ33793941-09334E1D-39F6-418A-87C8-EDC1F1AF9281Q33796046-84B98CB8-5803-474B-AC00-6DEB19EE0CB1Q33834727-3040B9AB-4F2B-44BC-8BB1-AE226EB30BB9Q33866690-D31BFA69-8E05-479B-A1A4-BB632EC7DB02Q33950653-3D775011-FD2E-42DE-87BF-0CB5958B2837Q34001406-1A6FF659-9568-47DD-BDBA-F5210B004AA1Q34034566-9E920A8C-995E-4DA9-B63F-078B60BE8E30Q34046139-202B01F7-48D2-4FD6-B51B-14F31870B94DQ34067969-3DD51181-D9A8-4A44-B0C4-DFF184D3EA52Q34115993-12600CDA-2A18-413D-9081-2C83C3AA0ABDQ34125555-23087C3A-44D0-472A-A6F5-E640F960329FQ34155038-0CE80542-AF0A-4408-95EA-373FFEFA0A5FQ34165218-AC8BEF04-0F26-4A3B-B585-E8DEA0404F08
P2860
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group
description
1994 nî lūn-bûn
@nan
1994 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Quality of life: a valid and r ...... e Prevention Trial Study Group
@ast
Quality of life: a valid and r ...... e Prevention Trial Study Group
@en
Quality of life: a valid and r ...... e Prevention Trial Study Group
@nl
type
label
Quality of life: a valid and r ...... e Prevention Trial Study Group
@ast
Quality of life: a valid and r ...... e Prevention Trial Study Group
@en
Quality of life: a valid and r ...... e Prevention Trial Study Group
@nl
prefLabel
Quality of life: a valid and r ...... e Prevention Trial Study Group
@ast
Quality of life: a valid and r ...... e Prevention Trial Study Group
@en
Quality of life: a valid and r ...... e Prevention Trial Study Group
@nl
P2093
P1433
P1476
Quality of life: a valid and r ...... e Prevention Trial Study Group
@en
P2093
A Archambault
E J Irvine
J W McDonald
R N Fedorak
P304
P356
10.1016/0016-5085(94)90585-1
P407
P577
1994-02-01T00:00:00Z